Live
- People voted for ideology, rejected dynasty: Sudhanshu Trivedi on Maha victory
- AP, Telangana to receive rains for next three days as low pressure to turn depression
- Kailash Gahlot inducted into BJP’s Delhi election panel
- With state elections over, Indian stock market heads for stability
- Mahayuti's Ladki Bahin Brahmastra demolishes MVA in Maharashtra
- Actor and Youth Ambassador Darasing Khurana Highlights Mental Health Issues with Singapore PM
- Heavy FII selling in India to taper off soon, say market watchers
- Esports Mania Grips India: What are the Trends Fueling this Growth?
- AI-Powered CRM: Shaping the Future of Customer Relationship Management
- AI and Fraud Prevention in Pharmacy: Fayazoddin Mohamad’s Vision for a Safer Industry
Molnupiravir barred from India's Covid treatment
The ICMR's National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid as of now, official sources said on Tuesday.
New Delhi: The ICMR's National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis.
This anti-Covid pill got the Drug Regulator General of India's approval on December 28 for restricted use in emergencies. Mutagenesis is a process by which the genetic information of an organism is changed by the production of mutation.
"Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns," an official source told PTI.
Indian Council of Medical Research (ICMR) chief Dr Balram Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for treatment.
"We have to remember that this drug has major safety concerns," he said, adding, it can cause defects in a developing fetus and can damage the muscles also. "Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," Dr Bhargava had said.
The UK Medicines and Healthcare products Regulatory Agency had on December 4 granted approval for Molnupiravir under special conditions for treatment of mild to moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
